High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo

BACKGROUND: Primary liver cancer is a lethal malignancy with a high mortality worldwide. Currently, sorafenib is the most effective molecular-targeted drug against hepatocellular carcinoma (HCC). However, the sorafenib resistance rate is high. The molecular mechanism of this resistance has not been...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Xiao, Yinzong, Sun, Lunquan, Fu, Yongming, Huang, Yan, Zhou, Rongrong, Hu, Xingwang, Zhou, Pengcheng, Quan, Jun, Li, Ning, Fan, Xue-Gong
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5731191/
https://ncbi.nlm.nih.gov/pubmed/29246127
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3868-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados